Press Room

Event

DDL 2022

Start
Wednesday, December 07, 2022 - 09:00
End
Friday, December 09, 2022 - 09:00
Location: Scotland, UK
Booth Number: 244

 

Visit Hovione’s booth at DDL next December 7-9 in Edinburgh and connect with one of our Inhalation Experts.

Schedule a meeting today
DDL – Drug Delivery to the Lungs
Stand #244

 

Hovione is a specialist integrated CDMO offering services for drug substance, drug product intermediate and drug product for oral and inhaled solutions. When looking for a fully Integrated Solution Provider for Inhalation, Hovione offers Customized high-performance APIs, Particle Engineering and Formulation along with a full range of highly specialized, innovative Inhalation Devices. 

Let’s discuss your project from feasibility to commercial.
 

 

In Edinburgh don’t miss Hovione’s poster presentations:

#39 - Evaluation of Performance of Dry Powder Inhaler Formulations by Laser Diffraction

Luís Sousa, Senior Analytical Scientist, R&D Analytical Development, Analytical Methodologies and Method Development

#48 - Capsule Filling of Spray Dried Powders for Inhalation using a Drum Filling technology: From Lab to Pilot Scale

Rui Churro, Scientist, R&D Inhalation & Advanced Drug Delivery, Process Development

#51 - Enhanced engineered formulations in dry powder inhalers for high dose lung delivery

Susana Saldanha, Manager, R&D Inhalation & Advanced Drug Delivery, Formulation Development

#53 - Simulation lung dissolution – fast-tracking DPI development

Hovione scientists with Inhalation Sciences

 

Schedule a meeting today

 

Find more about DDL2022

 

 

Also in the Press Room

See All

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
Hovione commitment to setting SBTs in line with the Paris Agreement

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of Hovione´s global expansion plans and marks a significant milestone in advancing Hovione's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote Hovione's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  “This strategic collaboration underscores Hovione's dedication to delivering innovative solutions and exceptional service to its customers,” said Yuken Kyoyama. “Our partnership with Higuchi will help to show customers in Japan how Hovione can meet their needs.”    Learn more about our business in Japan and visit our website hovione.co.jp    

News
Hovione proudly announces its collaborative venture with Higuchi.

Hovione forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Following the creation of offices in Shanghai and Beijing, Hovione is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance Hovione´s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about Hovione´s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that Hovione is renowned for worldwide.   “The launch of the Hovione Chinese website underscores our commitment to customers in China,” said Ms. Jackie Liu, Country Head, China. “By delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients´ unique challenges with agility and precision.” Visit us at www.hovione.com.cn    

News
Hovione is closer to its customers with a new website in Mandarin

Hovione launches new website for the Chinese Market

Jun 14, 2024

Also in Events

See All